A detailed history of Freestone Grove Partners LP transactions in Innoviva, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 20,823 shares of INVA stock, worth $359,196. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,823
Previous 19,875 4.77%
Holding current value
$359,196
Previous $360 Million 16.1%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

BUY
$17.1 - $21.8 $16,210 - $20,666
948 Added 4.77%
20,823 $418 Million
Q1 2025

May 15, 2025

SELL
$17.21 - $18.98 $326,129 - $359,671
-18,950 Reduced 48.81%
19,875 $360 Million
Q4 2024

Feb 14, 2025

BUY
$17.35 - $20.32 $673,613 - $788,924
38,825 New
38,825 $674 Million

Others Institutions Holding INVA

About Innoviva, Inc.


  • Ticker INVA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 69,706,000
  • Market Cap $1.2B
  • Description
  • Innoviva, Inc. engages in the development and commercialization of pharmaceuticals in the United States and internationally. Its products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a ...
More about INVA
Track This Portfolio

Track Freestone Grove Partners LP Portfolio

Follow Freestone Grove Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Freestone Grove Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Freestone Grove Partners LP with notifications on news.